ONYX-015: Phase II

Data from 30 evaluable patients showed an overall response of 63 percent for the combination of ONYX-015, cisplatin and 5-FU compared to a 35 percent historical chemotherapy response rate; 8 patients (27 percent) in the study had complete tumor regression compared to a historical complete response rate of <10 percent for chemotherapy alone.

For six months following treatment, 17 percent of the tumors progressed compared to a historical rate of 60-70 percent progression for chemotherapy alone. ...